Changing incidence and improved survival of gliomas.

[en] BACKGROUND: Tumours of the central nervous system (CNS) represent a relatively rare but serious health burden. This study provides insight into the incidence and survival patterns of gliomas in the Netherlands diagnosed in adult patients during the time period 1989-2010, with a focus on glioblastoma and low-grade gliomas. METHODS: Data on 21,085 gliomas (excluding grade I tumours) were obtained from the Netherlands Cancer Registry, including tumours of the CNS without pathological confirmation. We calculated the age-standardised incidence rates and the estimated annual percentage change (EAPC) for all glioma subtypes. Crude and relative survival rates were estimated using information on the vital status obtained from the Dutch Municipal Personal Records Database. RESULTS: Incidence of gliomas in adults increased over time, from 4.9 per 100,000 in 1989 to 5.9 in 2010 (EAPC 0.7%, p<0.001). Two thirds were astrocytoma, 10% oligodendroglioma/oligoastrocytoma, 3% ependymoma and 21% were unspecified. Within the group of astrocytic tumours, the proportion of glioblastoma rose, while the proportion of anaplastic and unspecified astrocytoma decreased. Unspecified neoplasms also decreased, but this was significant only after 2005. Over the course of the study period, glioblastoma patients more often received multimodality treatment with chemotherapy concomitant and adjuvant to radiotherapy. The crude two-year survival rate of glioblastoma patients improved significantly, from 5% in the time period 1989-1994 to 15% in 2006-2010, with median survival increasing from 5.5 to 9months. The incidence of low-grade gliomas did not change over time. Survival rates for low-grade oligodendroglial and mixed tumours show a modest improvement. CONCLUSIONS: The incidence rate for the total group of gliomas slightly increased, with a decrease of anaplastic and unspecified tumours and an increase of glioblastoma. Following the introduction of combined chemoradiation, two-year survival rates for glioblastoma significantly improved. Survival improved for low-grade gliomas except for low-grade astrocytic tumours.

Disciplines :

Genetics & genetic processes

Author, co-author :

Ho, Vincent K. Y.

Reijneveld, Jaap C.

Enting, Roelien H.

Bienfait, Henri P.

Robe, Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Baumert, Brigitta G.

Visser, Otto

Language :

English

Title :

Changing incidence and improved survival of gliomas.

Publication date :

2014

Journal title :

European Journal of Cancer

ISSN :

0959-8049

eISSN :

1879-0852

Publisher :

Elsevier, United Kingdom

Volume :

Issue :

Pages :

2309-18

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 08 September 2014

Statistics

Number of views

99 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

164

Scopus citations^®
without self-citations

148

OpenCitations

147

Bibliography

Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006; 2010.
B.A. Kohler, E. Ward, B.J. McCarthy, M.J. Schymura, L.A. Ries, and C. Eheman et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system J Natl Cancer Inst 103 9 2011 714 736
E. Crocetti, A. Trama, C. Stiller, A. Caldarella, R. Soffietti, and J. Jaal et al. Epidemiology of glial and non-glial brain tumours in Europe Eur J Cancer 48 10 2012 1532 1542
D.N. Louis, H. Ohgaki, O.D. Wiestler, and W.K. Cavanee WHO classification of tumours of the central nervous system 4th ed. 2007 IARC Press Lyon
R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 2005 987 996
R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 5 2009 459 466
I.R. Whittle The dilemma of low grade glioma J Neurol Neurosurg Psychiatry 75 Suppl. 2 2004 ii31 ii36
V.C. Prabhu, A. Khaldi, K.P. Barton, E. Melian, M.J. Schneck, and M.J. Primeau et al. Management of diffuse low-grade cerebral gliomas Neurol Clin 28 4 2010 1037 1059
F.F. Lang, and M.R. Gilbert Diffusely infiltrative low-grade gliomas in adults J Clin Oncol 24 8 2006 1236 1245
D. Schiff, P.D. Brown, and C. Giannini Outcome in adult low-grade glioma: the impact of prognostic factors and treatment Neurology 69 13 2007 1366 1373
L.D. Recht, R. Lew, and T.W. Smith Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31 4 1992 431 436
J.C. Reijneveld, M.M. Sitskoorn, M. Klein, J. Nuyen, and M.J. Taphoorn Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas Neurology 56 5 2001 618 623
M.L. van Veelen, C.J. Avezaat, J.M. Kros, W. van Putten, and C. Vecht Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery J Neurol Neurosurg Psychiatry 64 5 1998 581 587
M.J. van den Bent, T.J. Snijders, and J.E. Bromberg Current treatment of low grade gliomas Memo 5 3 2012 223 227
R. Soffietti, B.G. Baumert, L. Bello, A. von Deimling, H. Duffau, and M. Frenay et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force Eur J Neurol 17 9 2010 1124 1133
A.S. Jakola, K.S. Myrmel, R. Kloster, S.H. Torp, S. Lindal, and G. Unsgard et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas JAMA 308 18 2012 1881 1888
A.P. Polednak, and J.T. Flannery Brain, other central nervous system, and eye cancer Cancer 75 1 Suppl. 1995 330 337
M.H. Werner, S. Phuphanich, and G.H. Lyman The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly Cancer 76 9 1995 1634 1642
A. Helseth The incidence of primary central nervous system neoplasms before and after computerized tomography availability J Neurosurg 83 6 1995 999 1003
Z. Morris, W.N. Whiteley, W.T. Longstreth Jr, F. Weber, Y.C. Lee, and Y. Tsushima et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis BMJ 17 339 2009 b3016
J.M. Legler, L.A. Ries, M.A. Smith, J.L. Warren, E.F. Heineman, and R.S. Kaplan et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality J Natl Cancer Inst 91 16 1999 1382 1390
M.P. Houben, K.K. Aben, J.L. Teepen, A.Y. Schouten-Van Meeteren, C.C. Tijssen, and C.M. Van Duijn et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003 Acta Oncol 45 3 2006 272 279
J.G. Gurney, and N. Kadan-Lottick Brain and other central nervous system tumors: rates, trends, and epidemiology Curr Opin Oncol 13 3 2001 160 166
H. Ahsan, A.I. Neugut, and J.N. Bruce Trends in incidence of primary malignant brain tumors in USA, 1981-1990 Int J Epidemiol 24 6 1995 1078 1085
T.B. Johannesen, E. Angell-Andersen, S. Tretli, F. Langmark, and K. Lote Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999 Neuroepidemiology 23 3 2004 101 109
S. Lonn, L. Klaeboe, P. Hall, T. Mathiesen, A. Auvinen, and H.C. Christensen et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries Int J Cancer 108 3 2004 450 455
S. Hoffman, J.M. Propp, and B.J. McCarthy Temporal trends in incidence of primary brain tumors in the United States, 1985-1999 Neuro Oncol 8 1 2006 27 37
J.M. Kros Grading of gliomas: the road from eminence to evidence J Neuropathol Exp Neurol 70 2 2011 101 109
L.J. Schouten, P. Hoppener, P.A. van den Brandt, J.A. Knottnerus, and J.J. Jager Completeness of cancer registration in Limburg, The Netherlands Int J Epidemiol 22 3 1993 369 376
J. Berkel General practitioners and completeness of cancer registry J Epidemiol Community Health 44 2 1990 121 124
G.A. van der Sanden, P. Wesseling, L.J. Schouten, H.L. Teepen, and J. Coebergh A uniform histological cluster scheme for ICD-O-coded primary central nervous system tumors Neuroepidemiology 17 5 1998 233 246
L.E. Levesque, J.A. Hanley, A. Kezouh, and S. Suissa Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes BMJ 12 340 2010 b5087
A. Wohrer, T. Waldhor, H. Heinzl, M. Hackl, J. Feichtinger, and U. Gruber-Mosenbacher et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry J Neurooncol 95 3 2009 401 411
H. Ohgaki, and P. Kleihues Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J Neuropathol Exp Neurol 64 6 2005 479 489
M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, and M. Weller et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 2005 997 1003
A. Malmstrom, B.H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, and H. Schultz et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 9 2012 916 926
W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, and M. Simon et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 7 2012 707 715
M.J. van den Bent, A.A. Brandes, M.J. Taphoorn, J.M. Kros, M.C. Kouwenhoven, and J.Y. Delattre et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 31 3 2013 344 350
C.E. Pelloski, K.V. Ballman, A.F. Furth, L. Zhang, E. Lin, and E.P. Sulman et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 16 2007 2288 2294
H.S. Phillips, S. Kharbanda, R. Chen, W.F. Forrest, R.H. Soriano, and T.D. Wu et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 3 2006 157 173
C.L. Nutt, D.R. Mani, R.A. Betensky, P. Tamayo, J.G. Cairncross, and C. Ladd et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res 63 7 2003 1602 1607
F.B. Furnari, T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, and A. Stegh et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev 21 21 2007 2683 2710
H. Ohgaki, and P. Kleihues The definition of primary and secondary glioblastoma Clin Cancer Res 19 4 2013 764 772